Antibiotic Dosing in Pediatric Intensive Care

Conditions

Amikacin, Amoxicillin-clavulanate, Ciprofloxacin, Meropenem, Pharmacokinetics, Piperacillin-tazobactam, Teicoplanin, Vancomycin

Brief summary

Pharmacokinetics of antibiotics in critically ill neonates, infants and children

Dhont E, Standing JF, Beel E, Nguyen TVA, Herck I, Peperstraete H, Vandenberghe W, Bové T, Vandekerckhove K, Verougstraete N, Stove V, Vande Walle J, De Paepe P, De Cock PA.

2025-04-15

10.1016/j.ijantimicag.2025.107513

Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome*

Tatjana Van Der Heggen, Evelyn Dhont, Jef Willems, Ingrid Herck, Joris Delanghe et al. (10 authors)

Pediatric Critical Care Medicine2022-04-1517 citations

10.1097/pcc.0000000000002951

Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?

De Cock PA, Desmet S, De Jaeger A, Biarent D, Dhont E, Herck I, Vens D, Colman S, Stove V, Commeyne S, Vande Walle J, De Paepe P.

2017-03-0136 citations

10.1093/jac/dkw495

Augmented Renal Clearance Implies a Need for Increased Amoxicillin-Clavulanic Acid Dosing in Critically Ill Children

Pieter De Cock, Joseph F. Standing, Charlotte Barker, Annick De Jaeger, Evelyn Dhont et al. (10 authors)

Antimicrobial Agents and Chemotherapy2015-09-0980 citations

10.1128/aac.01368-15

Interventions

PROCEDUREblood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care

PROCEDUREblood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.

PROCEDUREblood sampling in patients receiving vancomycin as part of routine clinical care.

PROCEDUREblood sampling in patients receiving teicoplanin as part of routine clinical care.

PROCEDUREblood sampling in patients receiving meropenem as part of routine clinical care.

PROCEDUREblood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.

PROCEDUREblood sampling in patients receiving amikacin as part of routine clinical care.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 16 Years

Healthy volunteers

No

Inclusion criteria

* patients admitted to the pediatric intensive care unit * patient age/weight : 1,8 kg-15 years * patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines * intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)

Exclusion criteria

* no catheter in place for blood sampling * absence of parental/patient consent * known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides * extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )

Design outcomes

Primary

Measure	Time frame
To investigate if first-dose blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.	2 years (expected)
To investigate if steady-state blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.	2 years (expected)

Secondary

Measure	Time frame
To compare measured first-dose blood concentrations with predefined pharmacodynamic targets (Time above MIC)	2 years (expected)
To compare measured steady-state blood concentrations with predefined pharmacodynamic targets (Time above MIC)	2 years (expected)

Countries

Belgium

Contacts

CONTACTPieter De Cock, PharmD

pieter.decock@uzgent.be+32 9 332 29 69

PRINCIPAL_INVESTIGATORPieter De Cock

University Hospital, Ghent

Outcome results

None listed